A tech-only 24-marker screening profile for bone marrow specimens. An evaluation of specimen adequacy and cellular integrity will also be performed. Markers include CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD117, HLADR, Kappa and Lambda.

A flow cytometry profile, with additional rational marker selection for phenotyping (up to 35 total antibodies). An evaluation of specimen adequacy and cellular integrity will also be performed.

Available in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers tested by flow cytometry include cLambda, cKappa, CD5, CD10, CD19, CD20, CD45 and CD103.

The Sezary Syndrome Panel by flow cytometry aids in the diagnosis of Sezary syndrome and mycosis fungoides. Available in conjunction with, or after, a Diagnostic/Prognostic Profile result has been reported by Genoptix or client. Markers tested by flow cytometry include CD3, CD4, CD7, CD8, CD26 and
CD45

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), IGH (14q32.3), and TP53 (17p13.1) are included in the Myeloma Reflex FISH Profile (Enriched). If IGH positive, Genoptix will reflex to IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16) and IGH/MAFB t(14;20). Plasma cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD138 antibody.

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), IGH (14q32.3), and TP53 (17p13.1) are included in the Myeloma Reflex FISH Profile. If IGH positive, Genoptix will reflex to IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16) and IGH/MAFB t(14;20).

Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), TP53 (17p13.1), IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16), IGH/MAFB t(14;20) are included in the Myeloma FISH Profile (Enriched). Plasma cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD138 antibody.

Rearrangements of the PDGFRa (4q12), PDGFRb (5q32), FGFR1 (8p11), JAK2 (9p24.1) genes are detected by fluorescence in situ hybridization (FISH).

Cytogenetic abnormalities commonly associated with chronic myelogenous leukemia (CML) and CML in transformation are detected by fluorescence in situ hybridization (FISH). Probes for Cen 8 (+8), BCR/ABL1-ASS1 t(9;22), RARA (17q21.2)/(iso17q) are included in the CML FISH Profile.

Cytogenetic abnormalities commonly associated with chronic lymphocytic leukemia (CLL) are detected by fluorescence in situ hybridization (FISH). Probes for IGH/CCND1 t(11;14), ATM (11q22.3), Cen 12 (+12), 13q (13q-/-13), TP53 (17p13.1) are included in the CLL FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.